Objectives: Mycoplasma hominis is intrinsically resistant to 14-and 15-membered macrolides and to the ketolide telithromycin but is susceptible to josamycin, a 16-membered macrolide, and lincosamides. The aim of our study was to investigate the in vitro development of macrolide resistance in M. hominis and to study the impact of ribosomal mutations on MICs of various macrolides and related antibiotics.
Introduction
Mycoplasma hominis is a genital mycoplasma intrinsically resistant to 14-and 15-membered macrolides and to the ketolide telithromycin but susceptible to josamycin, a 16-membered macrolide, and lincosamides. 1, 2 This resistance has been mainly associated with a G2057A transition (Escherichia coli numbering) in domain V of 23S rRNA. 2 Strains with acquired resistance to macrolides have rarely been described. As two copies of the 23S rRNA gene are present in M. hominis, 2 both heterozygous and homozygous strains are expected. Two in vitro-selected mutants resistant to josamycin with A2062G or A2062T mutations in one or two alleles, respectively, have been reported. 3 Moreover, we described two clinical isolates with a macrolide-lincosamide-streptogramin B (MLS B ) resistance phenotype that harboured an A2059G substitution, alone or associated with a C2611U transition, on only the rrnB operon. 2 The aim of our study was to investigate the in vitro development of macrolide resistance in M. hominis and to study the impact of ribosomal mutations on MICs of various macrolides and related antibiotics.
Materials and methods
Selection of macrolide-resistant mutants was performed, as described previously, 4 by serial transfers of M. hominis in Hayflick modified broth medium supplemented with arginine, containing subinhibitory concentrations of clindamycin, pristinamycin, quinupristin/ dalfopristin and telithromycin. The M. hominis type strain PG21 (ATCC 23114), previously used for other selection studies, 3 0 , and MH23S-25). 2 When examination of the sequencing traces showed a mixture of bases at the altered residues, primers MH23S-A or MH23S-B, 2 designed to amplify each 23S rRNA gene independently, were used for amplification with primer MH23S-17 common to both alleles. The entire gene of protein L22 and a fragment of the L4 gene were also sequenced (primers MHL4-U, MHL4-R, MHL22-U and MHL22-R). 2 For two clones of mutants C5 and QD6, the entire 23S rRNA, L4 and L22 genes were sequenced. Pulsed-field gel electrophoresis of SalI and BamHI-digested genomic DNA was used to confirm that mutants were derived from the parental strain. 6 As expected, the macrorestriction digestion profile was identical to that of the parent strain (data not shown).
Results and discussion
MICs and ribosomal mutations observed in M. hominis PG21 mutants are shown in Table 1 and Figure 1 . The mutants selected at the 5th passage in the presence of clindamycin (mutant C5) and at the 6th and 12th passages in the presence of quinupristin/ dalfopristin (QD6 and QD12) harboured a C2611U substitution in the rrnB operon of the 23S rRNA gene. No other alteration was found in the entirely sequenced 23S rRNA or in the L4 and L22 protein genes of mutants C5 and QD6. For both mutants, MICs of erythromycin, azithromycin and telithromycin were significantly reduced with a 256-fold, 32-fold and 4-fold decrease, respectively ( Table 1) . Activities of other macrolides, lincosamides, streptogramins and ketolides (MLSKs) were not significantly modified. In M. hominis, the intrinsic resistance to 14-and 15-membered macrolides and telithromycin has been associated with a G2057A transition in domain V of 23S rRNA.
2 This mutation could lead to a disruption of the rRNA structure with an opening of the stem preceding the single-stranded portion of the peptidyl transferase loop. In mutants C5, QD6 and QD12, the C2611U transition hominis PG21 is the parental strain. Mutants selected in broth medium are designated by the initial of the selector antibiotic followed by the passage number. Twenty-five passages were performed for each selector antibiotic except for telithromycin (five passages). Only passages with a significant MIC increase (at least 4-fold) are presented in Table 1 . For these passages, two of the five clones subcultured were studied. Only MICs of one clone are shown since no significant difference (no more than one dilution) was observed between the susceptibilities of both clones. Their nucleotide sequences were always identical.
e Agar-selected mutants are designated by a prefix corresponding to the selection step (I or II) followed by the initial of the selector josamycin (J). Only clones with significant increased MICs and ribosomal mutations are shown. Mutant IIJ2 was generated from mutant IJ2 and mutant IIJ4 was generated from mutant IJ4.
appears to recreate a Watson-Crick base pair with the adenine at position 2057 ( Figure 1c ) and is associated with a loss of the intrinsic resistance to erythromycin and azithromycin and with a significant decrease in telithromycin MICs. It should be noted that in all cases the mutation of the sole rrnB operon was sufficient to significantly decrease MICs of the three antimicrobials. However, MICs remained higher than those reported for a susceptible mycoplasma, Mycoplasma pneumoniae. 1 Moreover, in M. pneumoniae, a base pair G2057-C2611 exists, and we described how a C2611A transversion, which disrupts this base pair, led to increased MICs of the same erythromycin, azithromycin and telithromycin antimicrobials. Consequently, the secondary structure of this portion of the peptidyltransferase loop seems to be strongly involved in the susceptibility of M. hominis and M. pneumoniae to these three MLSKs.
In mutant C10, an additional A2059G on the rrnB operon led to an MLS B resistance phenotype with a return to high-level resistance to erythromycin (MIC 512 mg/L) ( Table 1) . Interestingly, we reported the same association of C2611U and A2059G substitutions on the rrnB operon, which led to the same MLS B phenotype of resistance, in a clinical isolate of M. hominis. In mutant QD12, the C2611U substitution and an additional G2608C mutation were associated with a significant increase in streptogramin combination MICs, whereas erythromycin, azithromycin and telithromycin MICs remained unchanged compared with those for the QD6 mutant. To our knowledge, this mutation has never been associated with resistance to MLSKs.
In mutant T3, a G2056A transition on the rrnB operon was selected at the third passage in the presence of telithromycin. This mutation was associated with 4-and 8-fold increased MICs of azithromycin and telithromycin, respectively. It should be noted that this G2056A substitution disrupts another base pair in M. hominis (G2056-C2612) and could induce a more open conformation of the peptidyl transferase loop (Figure 1d ). At the sixth passage, mutants selected in the presence of pristinamycin harboured a C2586U substitution on the rrnB operon, which was associated with a 4-fold increased MIC of both streptogramin combinations. To date, mutations at position 2586 have never been associated with MLSK resistance, but the crystal structure analysis of the large subunit of Deinococcus radiodurans complexed with the quinupristin/dalfopristin combination revealed that a hydrogen bond exists between quinupristin and nucleotide 2586 (E. coli numbering). 7 However, the MIC of quinupristin was not significantly increased in mutant P6. In addition, a hydrogen bond also exists between base 2586 and azithromycin complexed to the 50S subunit of D. radiodurans, 8 but the azithromycin MIC was not affected in mutant P6. In mutant P25, an additional G792A mutation in domain II of 23S rRNA, also on operon rrnB, led to resistance to both streptogramin combinations and to increased MICs of josamycin. The MIC of telithromycin was also 4-fold higher than that for the parental strain. Nucleotide 792 is located in the loop connecting helices 32 and 35a (Figure 1b) , in close proximity to the base 790, which is involved in the binding of ketolides. 8, 9 This substitution was also observed on operon rrnA of the josamycin-resistant mutant IIJ4 obtained by agar selection (Table 1) .
Five josamycin-resistant mutants were obtained by agar stepwise selection. Mutant IJ2 harboured a G2576U substitution on the rrnA operon. This substitution has been associated with resistance to linezolid in Enterococcus spp. and Staphylococcus aureus. 10 However, the MIC of linezolid for the IJ2 mutant was identical to that for the parental strain PG21 (MIC 8 mg/L). Mutant IIJ2, generated from IJ2, presented an additional G2056A mutation also on the rrnA operon, which was associated with significantly increased MICs of azithromycin and telithromycin. Interestingly, the same G2056A substitution is carried by operon rrnB in mutant T3 and by operon rrnA in mutant IIJ2 and is associated with the same phenotype of resistance (Table 1) . To date, this is the first description of macrolideresistant mutants of M. hominis harbouring mutations on the rrnA operon. It should be noted that mutations on this operon were selected only by stepwise selection on agar medium, but this observation should be confirmed.
For the first time in M. hominis, mutations in ribosomal proteins L4 and L22 were observed in macrolide-resistant mutants. In the L22 protein, an arginine to lysine substitution at position 97 (mutant IJ1, M. hominis numbering) was associated with an MLS B phenotype. In the L4 protein, a histidine to leucine mutation at position 184 (mutants IJ4 and IIJ4) was associated with increased MICs of josamycin and streptogramin combinations and was previously reported in an in vitro-resistant mutant of M. pneumoniae (H70L, M. pneumoniae numbering). 4 Mutant IIJ4 harboured three mutations in L4 and 23S rRNA domains II and V that led to high-level resistance to macrolides, streptogramin combinations and telithromycin (Table 1) . Only clindamycin remained active against this mutant. Interestingly, alterations at position 2062 were previously associated with resistance to 16-membered macrolides and streptogramin combinations in M. hominis and M. pneumoniae. 3, 4 Moreover, the crystal structure of the 50S ribosomal subunit from D. radiodurans complexed with the quinupristin/dalfopristin combination indicates that both compounds have contacts with nucleotide 2062. 7 To summarize, a diversity of mutations can be selected in vitro with different macrolides and related antibiotics. Whereas most mutations were associated with increased MICs, the C2611U transition was unexpectedly associated with decreased MICs of erythromycin, azithromycin and telithromycin, leading to a loss of intrinsic resistance of M. hominis to erythromycin and azithromycin. Reconstruction of this mutation into a wild-type strain of M. hominis would prove its involvement in the phenotype observed. However, only a few genetic tools are available in mycoplasmas, especially in human species, and, at this time, directed mutagenesis through homologous recombination has not been successfully applied to M. hominis. Development of genetic tools for M. hominis is required to demonstrate the exact significance of the mutation observed.
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